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Abstract
Background: Many available data have suggested that hyperhomocysteinaemia, an established independent risk factor for
thrombosis (arterial and venous), may be associated with an increased risk of retinal vein occlusion (RVO).
Aim of the study: To evaluate homocysteine metabolism in consecutive caucasian patients affected by RVO from Northern
Italy.
Patients and Methods: 69 consecutive patients from Northern Italy (mean age 64.1 ± 14.6 yy) with recent RVO, were tested
for plasma levels of homocysteine (tHcy: fasting and after loading with methionine), cyanocobalamine and folic acid levels (CMIA-
Abbot) and looking for MTHFR C677T mutation (Light Cycler-Roche) and compared to 50 volunteers, enrolled as a control
group.
Results: Fasting levels of tHcy were significantly higher in patients than in controls: mean value 14.7 ± 7.7 vs 10.2 ± 8 nmol/ml.
Post load levels were also significantly higher: mean value 42.7 ± 23.7 vs 30.4 ± 13.3 nmol/ml; Total homocysteine increase was
also evaluated (i.e. ∆-tHcy) after methionine load and was also significantly higher in patients compared to control subjects: mean
∆-tHcy 27.8 ± 21.5 vs 21.0 ± 16 nmol/ml (normal value < 25 nmol/ml). Furthermore, patients affected by RVO show low folic
acid and/or vitamin B12 levels, although differences with control group did not reach statistical significance. Heterozygous and
homozygous MTHFR mutation were respectively in study group 46% and 29% vs control group 56% and 4%.
Conclusion: our data confirm that hyperhomocysteinaemia is a risk factor for RVO, and also that TT genotype of MTHFR
C677T is more frequently associated with RVO: if the mutation per se is a risk factor for RVO remains an open question to be
confirmed because another study from US did not reveal this aspect.
Hyperomocysteinemia is modifiable risk factor for thrombotic diseases. Therefore, a screening for tHcy plasma levels in patients 
with recent retinal vein occlusion could allow to identify patients who might benefit from supplementation with vitamins and 
normalization of homocysteine levels, in fasting and after methionine load.
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Background
Retinal vein occlusion (RVO) is a multifactorial disease
which may affect small, medium and large ocular vessels;
central vein occlusion represents the most dangerous clin-
ical entity [1]. However, RVO is considered an unusual
site of thrombosis [2]. Pathogenesis of RVO may recog-
nise a local disease such as glaucoma, ocular hyperten-
sion, optical neuropathy [3] and/or an underlying
systemic disease such as hypertension, diabetes, athero-
sclerosis, dyslipidemia, hyperviscosity syndrome, local or
systemic vasculytis [4-8]. Yet, also impairment of normal
haemostasis with a trend toward hypercoagulable state
has been described. Blandello et al. described increased
levels of prothrombin fragment 1+2 and d-dimer [9] and
Lijima et al. reported increased levels of thrombin-anti-
thrombin complexes in subjects affected by RVO [10].
Inherited thrombophilia related to clotting inhibitors
deficiency (i.e. protein C, Protein S and Antithrombin III
deficiencies) [11,12] has been rarely reported such as clot-
ting XII deficiency [13], while data on the role of factor V
Leiden are still matter of discussion [14-18] and few data
are available on the role of prothrombin A20210G gene
polymorphism in RVO pathogenesis [17,19]. Acquired
thrombophilia due to the presence of antiphospholipid
syndrome (primary or secondary to immunopathological
disease) is an established risk factor for RVO [20,21]. Also
hypofibrinolysis is a thrombotic risk factor for RVO. Plas-
minogen deficiency and 4G/5G gene polymorphism of
plasminogen activator inhibitor type 1, in fact, have been
recently described as risk factors for RVO [22,23].
Homocysteine is a sulphur-containing amino acid, which
results from the hydrolysis of S-adenosyl-homocysteine in
the methionine metabolic cycle. Several condition may
determine an increase of blood homocysteine such as an
inadequate folate intake with diet, smoking, drugs (i.e.
methotrexate, hormones, antiepileptic), renal failure and
inherited gene polymorphism of methylene-tetra-hydro-
folate-reductase (MTHFR). Increase in circulating homo-
cysteine may trigger endothelial dysfunction through oxi-
dative damage therefore inducing increased oxidation of
low density lipoprotein, stimulation of smooth muscle
cell proliferation and hypercoagulable state. Hyperhomo-
cysteinemia has been reported as risk factor for arterial
and/or venous thrombosis [24,25]. Yet, hyperhomo-
cysteinaemia has also been described as risk factor for
RVO [26], but data on large based population are still
lacking.
The aim of this study is to evaluate the role of homo-
cysteine metabolism in consecutive patients with RVO
from Northern Italy.
Patients and methods
Patients
We selected 69 consecutive caucasian patients from
Northern Italy (40 males and 29 females, mean age 64.1
± 14.6 years) affected by retinal vein occlusion (RVO).
RVO diagnosis was performed with fundus oculi examina-
tion and fluorangiography.
Thirtyeight/69 (55%) patients were affected by hyperten-
sion, 12/69 (17%) by diabetes, 18/69 (26%) by dyslipi-
demia, 4/69 (5%) by glaucoma, while 16/69 (23%) were
smokers; none of them had been diagnosed for hypervis-
cosity syndrome or vasculitis.
Risk factors for RVO in all patients are summarised in
table 1.
Table 1: Risk factor for RVO of study group and control subjects.
RVO subjects (69) CG subjects (50) P
Hypertension 38 (55%) 15 (30%) 0.014
Diabetes 12 (17%) 9 (18%) Ns
Glaucoma 6(8%) 0 (0%) 0.039
Hyperviscosity syndrome 0 (0%) 0 (0%) Ns
Vasculitis 0 (0%) 0 (0%) Ns
Smoking 16 (23%) 12 (24%) Ns
Dyslipidemia 18 (26%) 12 (24%) Ns
RVO: retinal vein occlusion
CG: control group
HYP: hypertension
DIAB: diabetes
SMOG: smoking
DYS: dyslipidemia
GLAU: glaucoma
HS: hyperviscosity syndrome
VASC: vasculytis
Ns: not significantThrombosis Journal 2005, 3:13 http://www.thrombosisjournal.com/content/3/1/13
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Anticardiolipin antibodies (IgM and IgG) anti-β2-glyco-
protein I antibodies and lupus anticoagulant were assayed
in all patients in order to detect antiphospholipid syn-
drome; so patients with antiphospholipid syndrome were
excluded from the study. Furthermore, none patient
showed kidney failure.
All patients agreed to enter in the study after an informed
consent was obtained.
Control group
As control group we selected 50 age-matched volunteers
of the same ethnic background (38 males and 12 females,
mean age 58.4 ± 12.2 years) without personal and familial
history of thrombotic disorders (i.e. previous venous and/
or arterial thrombosis). All subjects agreed to enter the
study after an informed consent was obtained. Fifteen/50
(30%) subjects were affected by hypertension, 9/50
(18%) by diabetes, 12/50 (24%) by dyslipidemia, while
12/50 (24%) were smokers; none of them had been diag-
nosed for glaucoma, hyperviscosity syndrome or vasculi-
tis. Risk factors for RVO of control subjects are also
summarised in table 1.
Common risk factors for RVO
Common risk factors for RVO (i.e. hypertension, diabetes,
smog, dyslipidemia, vasculitys, hyperviscosity syndrome,
glaucoma) were evaluated by a thorough anamnesis,
including questions concerning familial anamnesis, per-
sonal anamnesis and pharmacological anamnesis.
Methods
Whole blood samples were collected from all subjects
selected in the study by venipuncture from antecubital
vein in order to screen possible involvement of homo-
cysteine metabolism. Samples were collected nearly 5–7
days after diagnosis of RVO after an adequate treatment
had been started.
All patients were assayed for plasma homocysteine
(tHcy), fasting and after load with methionine, vitamin B
12 and folic acid levels and MTHFR C677T gene
polymorphism.
First blood sample
The first blood sample was collected in EDTA to screen
fasting homocysteine (FPIA-Abbot).
Second blood sample
Post-load homocysteine value was measured after
methionine administration (3.8 g/m2) per os. Homo-
cysteinaemia was tested on a blood sample collected after
four hours, then evaluated by collection of a new blood
sample in EDTA (FPIA-Abbot). No food containing
methionine was allowed in the interval.
We evaluated total homocysteine increase after oral load
of methyonine (i.e. ∆-tHcy) in the study group and in con-
trol subjects [27].
Third blood sample
The third blood sample was collected in SST II advanced
tube in order to detect serum folic acid levels and serum
vitamin B 12 levels (CMIA-Abbot).
Fourth blood sample
DNA was extracted using an automated procedure
(MagNA PURE, Roche, Italy). Patients were screened for
the C677T gene polymorphism of MTHFR using PCR
amplification with specific primers and Light Cycler appa-
ratus (Roche, Milan, Italy).
Statistical analysis
Data are expressed as mean ± standard deviation (SD) or
as number and percentage, as appropriate. Statistical anal-
ysis was performed with STATA 6 http://www.stata.com.
Significance of differences was assessed by Student's t test
for unpaired data, χ2 test or Fisher exact test as appropri-
ate; differences were considered to be significant if p <
0.05.
Results
Common risk factors for RVO were evaluated and are
summarised in table 1. Hypertension was present in 55%
of patients compared to 30% of control group (p: 0.014);
diabetes was present in 17% of patients compared to 18%
of control group (p: ns); smoking was present in 23% of
patients compared to 24% of control group (p: ns); dysli-
pidemia was present in 26% of patients compared to 24%
of control group (p: ns); glaucoma was present in 8% of
patients was absent in control subjects (p: 0.039); hyper-
viscosity syndrome and/or vasculytis were not found in
study group nor in control subjects (p: ns).
Fasting levels of homocysteinaemia were significantly
higher in study group than in control subjects (14.7 ± 9.9
vs 10.2 ± 8 nmol/ml, p: 0.02) (table 2).
Post-load levels of homocysteine (PL-Hcy) were also sig-
nificantly higher in study group than in control group
(42.7 ± 23.7 vs 30.4 ± 13.3 nmol/ml, p: < 0.01; normal
value < 38 nmol/ml), as far as total homocysteine increase
(∆-tHcy) (27.8 ± 21.5 vs 21.0 ± 16 nmol/ml, p: < 0.01;
normal value < 25 nmol/ml) (table 2).
∆-tHcy increase after methionine load was significantly
higher in study group than in control subjects (mean ∆-
tHcy 27.8 ± 21.5 vs 19.8 ± 16 nmol/ml, p: < 0.01; normal
value < 25 nmol/ml) (table 2).Thrombosis Journal 2005, 3:13 http://www.thrombosisjournal.com/content/3/1/13
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Serum folic acids levels were 6.27 ± 3.8 ng/ml in patients
vs 7.22 ± 3.5 ng/ml in control group (p: ns) (table 2),
while serum vitamin B 12 levels were 403.3 ± 202.1 pg/ml
in patients vs 512.6 ± 144.2 pg/ml in control subjects (p:
ns) (table 2). Three/69 (4%) patients of study group
showed low vitamin B 12 levels (i.e. < 150 pg/ml) vs none
in the control group, while 11/69 (15%) of patients
showed low folic acids levels (i.e. < 3 ng/ml) vs 2/50
(2.5%) in the control group. Among these, six patients
with low folic acid and/or vitamin B 12 serum levels
showed high fasting Hcy levels.
MTHFR C677T gene polymorphism was searched in 63/
69 patients (91%) and was found in 75% of patients. 29/
63 (46%) showed heterozigosity for MTHFR C677T gene
polymorphism, while 18/63 (29%) had homozigosity for
MTHFR C677T gene polymorphism. 48/50 subjects in the
control group underwent genetic test to detect MTHFR
C677T gene polymorphism: 27/48 (56%) showed hetero-
zygous mutation (p: ns), while 2/48 (4%) showed
homozygous mutation (p: 0.01) (table 2).
Discussion
RVO is a multifactorial disease which includes also retinal
vein thrombosis and its pathophysiology may be due to
local and/or systemic risk factor [1]. We may recognise
several types of RVO depending on the site of occlusion
(branch RVO, central RVO, hemicentral RVO) and for
localisation in large, medium or small-calibre veins; from
a clinical point of view RVO is usually associated with vis-
ual loss of variable degree. An association of RVO with
impairment of haemostasis with a trend toward hyperco-
agulable state has frequently been ruled out in case of ret-
inal vein thrombosis by several reports, but a clear
relationship seems to have been established only for
antiphospholipid syndrome [1,6,19]; other conditions,
such as inherited thrombophilia, are less commonly
described and the real incidence in these cases seems to be
different in several studies [13-18]. A possible explanation
could also be related to an ethnic background and to the
inclusion criteria of selected patients in the related studies.
However, according to available data thrombophilia
seems to be more frequent in young patients affected by
RVO [28].
In this field, hyperhomocysteinemia has recently been
identified as an emerging risk factor for RVO. Several
reports in last few years, in fact, described frequently
hyperhomocysteinemia in patients affected by RVO [29-
34]. In the same reports the real incidence seems to differ
not only for ethnical reasons but also for the difference in
the criteria used for the inclusion. A relationship between
hyperhomocysteinemia and RVO is well established for
young subjects, but a lot of available studies focused on
patients younger than 55 years [31,32]. Moreover, only a
few studies on this topic enrolled more than 50 patients,
such as the Blue Mountain Eye Study [28] and a meta-
analysis by Cahill et al from US [30], this being a possible
cause of underestimation of this issue. On the other hand,
only few studies evaluated homocysteine metabolism in a
more systematic way [31-35]. Although most studies
focused, in fact, on MTHFR C677T gene polymorphism,
not all researchers considered folate and vitamin B 12
serum levels.
In the present study we investigated homocysteinemia
and MTHFR C677T gene polymorphism and other
Table 2: Data of homocysteine metabolism parameters of study group and control subjects.
Test (unit of measurement) RVO subjects (69) GC subjects (50) P
Hcy (nmol/ml) 14.7 ± 9.9 10.2 ± 8 0.02
PL-Hcy (nmol/ml) 42.7 ± 23.7 30.4 ± 13.3 <0.01
∆-tHcy (nmol/ml) 27.8 ± 21.5 21.0 ± 16.0 <0.01
Serum folic acid (ng/ml) 6.27 ± 3.8 7.22 ± 3.5 Ns
Serum B12 vit. (pg/ml) 403.3 ± 202.0 601.6 ± 145.4 Ns
MTHFR C677T heterozigosity (%) 46,7 56,25 Ns
MTHFR C677T homozigosity (%) 29,3 4,17 <0.01
Hcy: homocysteine
PL-Hcy, post load homocysteine
∆-tHcy: total homocysteine increase
MTHFR: methylene tetra hydrofolate reductase
RVO: retinal vein occlusion
CG: control group
Ns: not significantThrombosis Journal 2005, 3:13 http://www.thrombosisjournal.com/content/3/1/13
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common variables associated to homocysteine metabo-
lism, such as folate and vitamin B 12 serum levels.
We found data that patients affected by RVO had hyper-
homocysteinemia, detected as fasting homocysteinemia
and as post-load homocysteinemia, and the differences
reached statistical significance (table 2). These data seem
to be in agreement with those previously reported by
other studies. However, this is the first report also show-
ing total increase of homocysteinemia (i.e. ∆-Hcy) evalu-
ated in patients affected by RVO and this difference also
reached statistical significance (table 2).
Serum folate and vitamin B12 levels were also tested
because strongly associated to homocysteine metabolism,
in terms of a possible therapeutical role. Although serum
folate and vitamin B12 levels were lower in patients com-
pared also to control subjects, these differences did not
reach statistical significance; however, also these data are
in agreement with data reported by Yildirim et al on small
population [33].
Yet, our data clearly show that hyperhomocysteinemia is
more frequent than other common known risk factors for
RVO, apart from hypertension and glaucoma (i.e. diabe-
tes, dyslipidemia, smoking, hyperviscosity syndrome, vas-
culytis) (table 1). Only glaucoma and hypertension
reached, in fact, statistical significance in patients affected
by RVO versus control subjects in our study (table 1), con-
firming a frequent and an interesting possible pathophys-
iological role of homocysteine metabolism in RVO.
Moreover, the role of hyperhomocysteinemia in patients
affected by RVO seems to be confirmed also by the high
frequency of MTHFR C677T homozigosity in patients
affected by RVO compared to control group (table 2). The
TT genotype, in fact, has been associated more frequently
to hyperhomocysteinemia, although this high incidence
of TT genotype could be associated also to an ethnic back-
ground. This could be relevant because an epidemiologi-
cal study written by Cappuccio et al underlined that TT
genotype is more frequent in Caucasian subjects com-
pared to Asian subjects [36] and a previous study by
Cahill et al. [30] on subjects from US revealed that hyper-
homocysteinemia but not TT genotype of MTHFR was a
risk factor for RVO. So, although further studies on large
based population should be performed also from a
genetic point of view; our data suggest a prompt screening
for homocysteine metabolism and MTHFR C677T gene
polymorphism (in particular for Caucasian subjects) in
patients affected by RVO. Further studied could also be
addressed to understand also the role of another emerging
MTHFR gene polymorphism (i.e. A1298C) sometime
associated to hyperhomocysteinemia [37], alone and/or
in association with MTHF C677T gene polymorphism, in
large based population affected by RVO.
In conclusion, based on this study, we suggest a careful
investigation on several metabolic parameters related to
homocysteine metabolism in patients affected by RVO. A
screening for hyperhomocysteinemia should be promptly
performed particularly in patients without other common
risk factors for RVO. These studies could have in fact a
deep impact also on therapeutical aspects in order to bet-
ter understand a possible role of folic acid and vitamin
B12 fortification in the management of RVO.
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